NAD+ Therapy — What Richmond Patients Need to Know

NAD+ Therapy — What Richmond Patients Need to Know

A study published in Cell Metabolism in 2022 found that NAD+ levels decline by approximately 50% between the ages of 40 and 60. A reduction that directly correlates with impaired mitochondrial function, reduced cellular energy production, and accelerated biological aging. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the human body, critical for converting nutrients into ATP (adenosine triphosphate), the cellular energy currency. When NAD+ levels drop, so does the cell's capacity to repair DNA, manage oxidative stress, and maintain metabolic efficiency.

Our team has reviewed this intervention across hundreds of client inquiries looking for cellular optimization strategies. The gap between the biology and the marketing is wider than most clinics acknowledge. And that distinction matters when you're deciding whether to spend $500 per infusion.

What is NAD+ therapy, and how does it work at the cellular level?

NAD+ therapy delivers nicotinamide adenine dinucleotide directly into the bloodstream through intravenous infusion, bypassing gastrointestinal degradation that limits oral NAD+ precursors. The infused NAD+ enters cells and activates sirtuins. Enzymes that regulate DNA repair, inflammation control, and mitochondrial biogenesis. The mechanism is straightforward: more available NAD+ means more active sirtuins, which theoretically translates to improved cellular resilience and metabolic function.

NAD+ Therapy Misconception Most Richmond Providers Don't Clarify

Yes, NAD+ is essential for cellular energy production. But delivering it intravenously doesn't guarantee bioavailability at the mitochondrial level the way the marketing implies. NAD+ is a large, charged molecule that doesn't cross cellular membranes efficiently without specific transport proteins. While IV infusion does increase plasma NAD+ concentrations temporarily, the degree to which exogenous NAD+ reaches intracellular compartments where it's metabolically active remains contested in the literature. Most published trials use NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). Not direct NAD+. Because precursors cross membranes more readily and convert to NAD+ inside the cell. This article covers how NAD+ therapy is administered, what the current evidence actually supports, and what Richmond patients should ask providers before booking.

The Biological Mechanism Behind NAD+ and Cellular Aging

NAD+ functions as both a coenzyme in redox reactions (transferring electrons between molecules) and as a substrate for enzymes that regulate gene expression and DNA repair. When NAD+ binds to sirtuins. A family of seven proteins (SIRT1–SIRT7). It enables them to remove acetyl groups from histones and other proteins, modulating gene transcription related to stress resistance, inflammation suppression, and mitochondrial function. SIRT1 activation, specifically, has been shown in animal models to extend lifespan and delay age-related diseases including metabolic syndrome and neurodegeneration.

The decline in NAD+ with age is driven by three factors: reduced synthesis (via the salvage pathway enzyme NAMPT), increased consumption (by enzymes like CD38 and PARPs that use NAD+ for DNA repair and immune signaling), and mitochondrial dysfunction that impairs NAD+ recycling. The result: by age 60, most adults have half the NAD+ levels they had at 20, and the cellular machinery that depends on NAD+ operates less efficiently.

Our experience shows that patients seeking NAD+ therapy are typically drawn by claims about energy restoration, cognitive clarity, or anti-aging benefits. The mechanistic plausibility is real. NAD+ does underpin these processes. But translating that mechanism into measurable clinical outcomes in humans is where the evidence gets thinner.

What Richmond NAD+ Therapy Sessions Actually Involve

NAD+ therapy in Richmond is delivered as an intravenous infusion administered in a clinical setting. Typically a wellness clinic, integrative medicine practice, or IV therapy lounge. Sessions last 2–4 hours depending on dose and individual tolerance. Standard protocols range from 250mg to 1,000mg per session, infused slowly to minimize side effects. The infusion must be titrated carefully because rapid administration causes flushing, chest tightness, and nausea in most patients. These are not allergic reactions but direct effects of NAD+ on vascular and autonomic nervous system receptors.

Patients sit in a recliner during infusion. Vital signs are monitored. If discomfort occurs, the infusion rate is reduced. Most providers recommend an initial series of 4–10 sessions spaced 1–2 days apart, followed by monthly maintenance infusions. The total initial cost for a 10-session protocol at 500mg per session runs $4,000–$6,000 in Richmond. Not covered by insurance.

The Blunt Honest Answer: NAD+ infusions are time-intensive, expensive, and uncomfortable for many patients. If you're considering it because you read it 'reverses aging,' you should know the evidence for that claim in humans is essentially anecdotal.

NAD+ Therapy vs Oral NAD+ Precursors: Clinical Evidence Comparison

The table above shows the core distinction Richmond patients need to understand: oral NAD+ precursors like NR and NMN have more robust human clinical trial data demonstrating intracellular NAD+ increases than IV NAD+ itself. The IV route delivers a larger acute dose, but whether that translates to better outcomes remains unproven in head-to-head trials.

Key Takeaways

• NAD+ is a coenzyme critical for mitochondrial function, DNA repair, and sirtuin activation. Levels decline approximately 50% between ages 40 and 60.
• IV NAD+ therapy delivers 250–1,000mg per session over 2–4 hours, bypassing GI degradation but with uncertain intracellular uptake efficiency compared to oral precursors.
• Richmond NAD+ therapy costs $400–$800 per session; most protocols recommend 4–10 initial sessions followed by monthly maintenance.
• Published human trials predominantly use oral NAD+ precursors (NR, NMN) rather than IV NAD+. The evidence base for IV delivery is weaker than most clinic marketing suggests.
• Side effects during infusion include flushing, nausea, chest tightness, and cramping. These resolve when infusion rate is reduced.
• Oral NAD+ precursors cost $50–$120/month and show 40–90% increases in blood NAD+ levels in randomized controlled trials. A more cost-effective starting point for most patients.

What If: NAD+ Therapy Richmond Scenarios

What If I Try NAD+ Therapy and Feel Nothing After the First Session?

Continue the protocol before evaluating efficacy. Single-session effects are highly variable. Most patients report subjective benefits (improved energy, mental clarity) after 3–5 sessions, though these reports are difficult to separate from placebo effects given the lack of blinded trials. If you complete a 6–10 session protocol and notice no difference, oral NAD+ precursors or mitochondrial cofactors (CoQ10, L-carnitine) may be more appropriate.

What If the Infusion Causes Severe Nausea or Chest Discomfort?

Inform the provider immediately. The infusion rate should be reduced or paused. These symptoms result from rapid NAD+ binding to purinergic receptors in smooth muscle and autonomic nerves, not from toxicity. Slowing the drip resolves symptoms within minutes. If symptoms persist despite rate adjustment, the session should be discontinued and the dose reduced for the next visit. NAD+ therapy isn't inherently unsafe, but individual tolerance varies.

What If I'm Already Taking Oral NR or NMN — Should I Still Do IV NAD+ Therapy?

There's no published evidence that combining oral NAD+ precursors with IV NAD+ produces additive benefits. If you're already seeing results from oral supplementation, adding IV therapy may be redundant and expensive. The mechanistic rationale for stacking them is weak. Both routes ultimately increase intracellular NAD+, and there's no data suggesting higher doses produce proportionally greater outcomes.

The Unflinching Truth About NAD+ Therapy

Here's the honest answer: NAD+ therapy is biologically plausible, mechanistically interesting, and poorly supported by rigorous human clinical trials. The sirtuin-NAD+ aging hypothesis is compelling in animal models. Caloric restriction, resveratrol, and NAD+ boosting all extend lifespan in mice and delay age-related pathologies. But translating that to humans has been harder than expected. The clinical trials that do exist overwhelmingly use oral NAD+ precursors, not IV NAD+, and most measure blood NAD+ levels rather than clinical endpoints like functional capacity, cognitive performance, or disease markers.

The IV route costs 20–40 times more than oral precursors per month and requires hours of clinic time. If the goal is raising intracellular NAD+, starting with oral NR or NMN at $60–$100/month is the rational first step. If that doesn't produce noticeable improvement after 8–12 weeks, IV therapy becomes a reasonable escalation. But it shouldn't be the entry point based on current evidence.

We've worked with clients who swear by NAD+ infusions and clients who found them underwhelming. The subjective response rate appears high, but subjective responses in unblinded protocols are notoriously unreliable. Richmond providers offering NAD+ therapy are not practicing bad medicine. They're offering an intervention with a strong mechanistic foundation and weak clinical validation. That's not the same as offering something proven.

What Richmond Patients Should Ask Before Booking NAD+ Therapy

Before committing to a $4,000–$6,000 NAD+ protocol, ask the provider these questions: (1) What specific clinical outcomes should I expect to see, and in what timeframe? (2) Do you measure blood NAD+ levels before and after treatment to verify the intervention worked biochemically? (3) Have you compared patient outcomes between IV NAD+ and oral NR/NMN in your practice? (4) What happens if I don't notice improvement after 6 sessions. Is there a refund or alternative protocol?

Most wellness clinics offering NAD+ therapy don't measure NAD+ levels. They rely on subjective patient reports. That's a red flag. If the mechanism is 'raising NAD+ improves cellular function,' the provider should verify that NAD+ actually increased. Blood NAD+ testing is available through specialty labs and costs approximately $150–$250. A provider unwilling to order it is asking you to spend thousands on an unmeasured outcome.

Richmond has at least six clinics offering NAD+ infusions as of 2026. Competition has driven prices down slightly but hasn't improved transparency around evidence quality. If you're seeking NAD+ therapy for a specific condition (chronic fatigue, cognitive decline, addiction recovery), ask whether published trials support that indication. For chronic fatigue, the evidence is minimal. For addiction, there are small pilot studies suggesting benefit during withdrawal, but no large RCTs. For 'anti-aging,' the evidence is almost entirely preclinical.

NAD+ therapy won't harm you if administered properly, but it might not help you either. And at $500 per session, the opportunity cost is significant. The information in this article is for educational purposes. Treatment decisions should be made in consultation with a licensed healthcare provider familiar with your medical history.

There's a reason NAD+ research focuses on oral precursors despite IV delivery being available for decades: oral administration is cheaper, easier to study in large populations, and produces measurable intracellular NAD+ increases in controlled trials. If IV NAD+ were dramatically superior, the research would have shifted by now. It hasn't. That doesn't mean IV therapy is useless. It means the evidence hierarchy doesn't support it as a first-line intervention yet. If you're considering NAD+ therapy in Richmond, start with the cheapest, best-studied option (oral NR or NMN) and escalate to IV only if oral supplementation fails to produce the outcomes you're seeking after 8–12 weeks of consistent use.